| 000 | 01410 a2200385 4500 | ||
|---|---|---|---|
| 005 | 20250517052720.0 | ||
| 264 | 0 | _c20160517 | |
| 008 | 201605s 0 0 eng d | ||
| 022 | _a1532-6535 | ||
| 024 | 7 |
_a10.1002/cpt.263 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aYang, E | |
| 245 | 0 | 0 |
_aPCSK9 Inhibitors: Are We on the Verge of a Breakthrough? _h[electronic resource] |
| 260 |
_bClinical pharmacology and therapeutics _cDec 2015 |
||
| 300 |
_a590-601 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadverse effects |
| 650 | 0 | 4 |
_aAnticholesteremic Agents _xadverse effects |
| 650 | 0 | 4 |
_aBiomarkers _xblood |
| 650 | 0 | 4 |
_aCardiovascular Diseases _xetiology |
| 650 | 0 | 4 |
_aCholesterol, LDL _xblood |
| 650 | 0 | 4 | _aDiffusion of Innovation |
| 650 | 0 | 4 |
_aDrug Discovery _xtrends |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypercholesterolemia _xblood |
| 650 | 0 | 4 |
_aMolecular Targeted Therapy _xtrends |
| 650 | 0 | 4 | _aProprotein Convertase 9 |
| 650 | 0 | 4 |
_aProprotein Convertases _xantagonists & inhibitors |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 |
_aSerine Endopeptidases _xgenetics |
| 650 | 0 | 4 |
_aSerine Proteinase Inhibitors _xadverse effects |
| 773 | 0 |
_tClinical pharmacology and therapeutics _gvol. 98 _gno. 6 _gp. 590-601 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/cpt.263 _zAvailable from publisher's website |
| 999 |
_c25260883 _d25260883 |
||